VISCHER advises Artiria Medical on $6m raise
Artiria Medical, a Swiss neurovascular MedTech company developing next-generation neuro interventional products for stroke and aneurysms, closed a USD 6m series A2 financing round. The round was led by 4FOX Ventures, with the Wyss Center for Bio and Neuroengineering joining several of the company’s existing investors. The funds will be used to advance clinical studies in stroke in Europe and the U.S.
The VISCHER team advising Artiria Medical SA in this transaction included (pictured from left to right) Matthias Staehelin (Partner, Corporate/M&A) and Vincent S. Reardon (Managing Associate, Corporate/M&A).
